Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …

Purpose: Resistance to third-generation EGFR inhibitors including osimertinib arises in part
from the C797S mutation in EGFR. Currently, no targeted treatment option is available for …

Introduction Lorlatinib was found to have activity in ALK-positive NSCLC in a global phase 1
and 2 study. We report an ongoing phase 2 study in Chinese patients with ALK-positive …

Introduction Randomized controlled trials have investigated different first-line treatments for
patients with advanced EGFR-mutated NSCLC. Nevertheless, their efficacy, in particular, the …

Objective: Dacomitinib has been approved for non-small-cell lung cancer (NSCLC) patients
harboring classical epidermal growth factor receptor (EGFR) mutations; however, clinical …

Rationale and Objectives This study aimed to non-invasively predict epidermal growth factor
receptor (EGFR) mutation status in patients with lung adenocarcinoma using multi-phase …

Background Dacomitinib is the second‐generation epidermal growth factor receptor (EGFR)‐
tyrosine kinase inhibitor (TKI) for mutant non–small cell lung cancer (NSCLC). EGFR‐TKIs …

Patients with epidermal growth factor receptor (EGFR) exon 21 L858R substitution benefit
less from standard EGFR tyrosine kinase inhibitor (TKI) treatment, and whether anti …

Simple Summary Survival benefits and clinical responsiveness have been exhibited by
various generations of EGFR-tyrosine kinase inhibitors (TKIs) in numerous randomized …

Introduction Osimertinib is the treatment of choice for epidermal growth factor receptor
(EGFR)-mutated advanced non–small-cell lung cancer (NSCLC). Because of its high price …